D. A. Vyzhigin

D. A. Vyzhigin

Auto-generated profile, based on publicly available information

D. A. Vyzhigin

Russian University of Medicine

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2025 in Kardiologiia
Verified
Journal Article
Open access
PDF file
YVYu. A. Vasyuk
Yu. A. Vasyuk
СМСергей Муслов
Сергей Муслов
DVD. A. Vyzhigin
D. A. Vyzhigin
ESE. Yu. Shupenina
E. Yu. Shupenina
ENE. O. Novosel
E. O. Novosel
It is known that the advances in cancer treatment leading to increased survival in malignant neoplasms, entail a variety of adverse cardiovascular toxic effects that can be quite serious and even potentially fatal. An important component that influences the degree of cardiotoxicity risk is the patient’s clinical and functional state and the cardiovascular history at the time of cancer diagnosis. This information can be used in practice for the cardiovascular screening and clinical and functional evaluation of a patient with a neoplasm before the start of antitumor therapy. After completion of the cardiotoxic therapy, as well as during subsequent follow-up, it is advisable to re-evaluate the risk of long-term cardiotoxicity to determine the frequency and intensity of cardiovascular monitoring. For convenience of calculating the risk of cardiotoxicity in cancer patients undergoing the antitumor treatment, the authors of this article have developed two computer programs that can be used as PC applications (https://disk.yandex.ru/d/NuhzYnicWo9FSw) and on mobile devices (https://disk.yandex.ru/d/uXAriKZ6qhkULA.). These programs facilitate the selection of the correct strategy for the management of cancer patients that is aimed at reducing the likelihood of cardiotoxic complications of the antitumor treatment.

5 January 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
YVYu. A. Vasyuk
Yu. A. Vasyuk
ESE. Y. Shupenina
E. Y. Shupenina
ENE. O. Novosel
E. O. Novosel
DVD. A. Vyzhigin
D. A. Vyzhigin
ANA. G. Nosova
A. G. Nosova
ЮВЮ. А. Васюк
Ю. А. Васюк
Aim. To search early signs of cardiotoxicity in patients receiving anticancer therapy and evaluate the effectiveness of cardioprotection with an angiotensin-converting enzyme inhibitor, beta-blocker and myocardial cytoprotector.Material and methods. The study included 98 patients with high and very high risk of cardiotoxicity according to the Mayo Clinic scale (USA). Cancer patients with hypertension were offered cardioprotective treatment with a fixed-dose combination of perindopril and bisoprolol, and patients with very high risk and concomitant coronary artery disease additionally trimetazidine.The patients were divided into 2 following groups: the experimental group (n=50), where patients were prescribed cardioprotective therapy, and the control group (n=48), which consisted of patients who refused or had contraindications to cardioprotection. All patients underwent an examination, including the collection of complaints and anamnesis, physical examination, electrocardiography and echocardiography with an assessment of left ventricular (LV) global longitudinal strain before chemotherapy and 1, 3, 6, 9 and 12 months after initiation of anticancer therapy.Results. In patients of the control group, by the end of the follow-up, the left atrial volume index and LV end-diastolic volume index significantly increased. In the main group, these indicators did not change significantly. In the control group, by the final visit, the LV ejection fraction significantly decreased in comparison with the initial value and the value in the first group. After 6, 9 and 12 months, there was a significant decrease in the LV global longitudinal strain in the control group, while in the main group this indicator remained within the normal range. The mortality rate in the control group was significantly higher (15% vs 2% in the experimental group). In the experimental group, cardiotoxic complications occurred in 28%, while in the control group — in 78% of patients.Conclusion. The study demonstrated the significant importance of cardiac monitoring and primary drug prevention of cardiotoxicity of anticancer therapy. A sig nificant deterioration in LV systolic function was shown in patients with a high and very high risk of cardiotoxicity who did not receive cardioprotective therapy, while its high efficiency was demonstrated in patients of the experimental group.

6 May 2020 in Therapy
Verified
Journal Article
Closed access
MMMaychuk E.YU. Maychuk
Maychuk E.YU. Maychuk
VVVoevodina I.V. Voevodina
Voevodina I.V. Voevodina
VVVyzhigin D.A. Vyzhigin
Vyzhigin D.A. Vyzhigin
ARA.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

12 May 2023 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
YVYu. A. Vasyuk
Yu. A. Vasyuk
ESE. Y. Shupenina
E. Y. Shupenina
ANA. G. Nosova
A. G. Nosova
ENE. O. Novosel
E. O. Novosel
DVD. A. Vyzhigin
D. A. Vyzhigin
Cardiovascular and oncological diseases are the leading causes of adult death in the world. Despite proven efficacy, anticancer drugs can cause severe cardiovascular complications. Recently, data have appeared on the possible vasotoxic effects of chemotherapy drugs, which can manifest themselves as the progression of arterial hypertension and atherosclerosis, the development of myocardial ischemia and acute coronary syndrome, the formation of venous and arterial thrombosis. The key mechanism for the development of vasotoxicity is endothelial dysfunction, and anticancer drugs can also affect the processes of thrombosis. The review presents the results of 12 selected observational retro- and prospective studies involving cancer patients receiving presumably vasotoxic therapy. Data on the frequency of occurrence and possibilities for the prevention of vasotoxicity are presented.

11 January 2022 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
YVYu. A. Vasyuk
Yu. A. Vasyuk
ESE. Yu. Shupenina
E. Yu. Shupenina
DVD. A. Vyzhigin
D. A. Vyzhigin
ENE. O. Novosel
E. O. Novosel
KGK. V. Gallinger
K. V. Gallinger
Cancer is the second leading cause of mortality in the world, second only to cardiovascular diseases. Simultaneously cancer mortality has been steadily decreasing due to the development of new chemotherapy and targeted drugs and the improvement of existing treatment protocols. Improving the prognosis of treatment of cancer patients leads to an unexpected result - more patients are faced with side effects of cancer treatment. Cardiotoxicity, including arrhythmia, has become a significant factor to reduce the effectiveness of cancer patient’s treatment. Atrial fibrillation is frequent and persistent a rhythm disorder, affecting all categories of patients, especially the elderly. An association between these two conditions can be expected, considering the fact that in old age the prevalence of malignant neoplasms and comorbid pathology predisposing to the onset of AF is high. Therefore, AF may be an additional factor negatively influencing the prognosis and treatment tactics in patients with malignant neoplasms. A comprehensive search was conducted using the keywords “cancer”, “atrial fibrillation” and “cardiotoxicity” using the PubMed, Scopus and Cohrane databases. We reviewed publications having the relationship between AF and cancer. The literature review considered 61 publications on the prevalence of AF in cancer patients, classification, mechanisms of development, the effect of anticancer drugs and other treatment methods on this group of patients. Analyzed articles include clinical guidelines, consensus expert opinions, systematic reviews, meta-analyzes, and previously published reviews of the literature. The problem of cardiotoxic complications diagnostics is evaluated separately, incl. arrhythmias, and their monitoring in cancer patients. Therefore, the direction of medicine named "Cardio-oncology" comes to the fore. Interdisciplinary interaction will allow identify cardiotoxic manifestations at the subclinical stage and optimize anticancer treatment.

22 August 2025 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
YVYu. A. Vasyuk
Yu. A. Vasyuk
DVD. A. Vyzhigin
D. A. Vyzhigin
ESE. Y. Shupenina
E. Y. Shupenina
ENE. O. Novosel
E. O. Novosel
EUE. A. Ulyanova
E. A. Ulyanova
Aim. To study new possibilities of the potential of speckle tracking echocardiography for detecting early subclinical cardiotoxicity of chemo- and targeted therapy.Material and methods. 150 patients with a verified oncological diagnosis, with a very high or high risk of cardiotoxicity, determined by the Mayo Clinic scale, were included in the prospective observational study at the Department of Hospital Therapy No. 1 of the Russian Medical University of the Ministry of Health of Russia in 2021-2023. All enrolled patients were recommended to take a fixed combination of the ACE inhibitor perindopril and the beta-blocker bisoprolol (5+5 mg) 5-7 days before the start of chemo-targeted therapy. Patients with a very high risk of cardiotoxicity who were diagnosed with ischemic chronic heart failure or stable coronary artery disease, or post-myocardial infarction, were additionally recommended to take long-acting trimetazidine OD at a dose of 80 mg once daily. At the second visit, the main group (n=84, receiving cardioprotective drugs) and the comparison group (n=66, not receiving cardioprotective drugs) were formed. All patients at the time of inclusion in the study, as well as 1, 3, 6, 9 and 12 months after the start of antitumor therapy, underwent the following assessment: collecting complaints, anamnesis data, physical examination, ECG registration in 12 standard leads, and a two-dimensional echocardiogram with the measurement of left ventricular (LV) global longitudinal strain (GLS).Results. Primary drug prophylaxis in cancer patients with high and very high risk of cardiotoxicity was associated with a 2.7-fold decrease in significant cardiovascular complications. The development of chronic heart failure in the main group was noted 7 times less frequently than in the comparison group (n=1 (1.2%) vs n=7 (10.6%), p<0.05), a decrease in GLS LV 2.6 times (n=5 (5.9%) vs n=13 (19.7%), p-18%, compensatory hyperkinesia of LV apical segments contractility <-18% in the inner part of the diagram compared to the initially determined values of the LV longitudinal strain before the start of antitumor therapy is an early, preclinical sign of cardiotoxicity.Conclusion. The detection of typical changes in local longitudinal strain should be considered as an early sign of cardiotoxicity with a subsequent change in treatment tactics: temporary or permanent withdrawal of the drugs that caused cardiovascular complications, the appointment of cardioprotective therapy with ACE inhibitors, beta-adrenergic blockers and myocardial cytoprotectors.